Interleukin-1 Blockade in Acute Myocardial Infarction to Prevent Heart Failure
Status:
Not yet recruiting
Trial end date:
2027-12-01
Target enrollment:
Participant gender:
Summary
Patients who have a heart attack are at high risk for future development of heart failure
('weakening of the heart'). The researchers believe that the reaction of the heart muscle to
injury (inflammation) during a heart attack may be contributing to the risk of heart failure.
The current study will test the ability of an anti-inflammatory medicine (anakinra) to block
the inflammation in the body during and after a heart attack.